Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations

被引:20
作者
Brauers, J.
Kresken, M.
Menke, A.
Orland, A.
Weiher, H.
Morrissey, I.
机构
[1] Antiinfect Intelligence GmbH, D-53359 Rheinbach, Germany
[2] Univ Appl Sci, D-53359 Rheinbach, Germany
[3] GR Micro Ltd, London NW1 3ER, England
关键词
bactericidal effect; time-kill methodology; daptomycin; glycopeptides; linezolid;
D O I
10.1016/j.ijantimicag.2006.10.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The bactericidal activities of daptomycin, vancomycin, teicoplanin and linezolid at human peak free serum concentrations (C-max,(free)) were determined against Staphylococcus aureus (one methicillin-susceptible and two methicillin-resistant strains), Enterococcusfaecalis and Enterococcus faecium (one vancomycin-susceptible and one vancomycin-resistant strain of each). Daptomycin was rapidly bactericidal against 7/7 strains at C-max,(free), of 22.0 mg/L (corresponding to 63% protein binding) and against 3n strains at 4.8 mg/L (corresponding to 92% protein binding). Vancomycin (18.0 mg/L) was bactericidal against only two strains. Both teicoplanin (4.5 mg/L) and linezolid (10.4 mg/L) were consistently bacteriostatic. Daptomycin is a useful option for the treatment of Gram-positive infections owing to its strong bactericidal activity. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:322 / 325
页数:4
相关论文
共 11 条
[1]   Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].
Carpenter, CF ;
Chambers, HF .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000
[2]  
Craig W., 2004, 42 ANN M INF DIS SOC
[3]  
Cruciani M, 1996, J ANTIMICROB CHEMOTH, V38, P865
[4]   Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects [J].
Dvorchik, BH ;
Brazier, D ;
DeBruin, MF ;
Arbeit, RD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1318-1323
[5]   Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections [J].
Eisenstein, BI .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) :1159-1169
[6]   EUCAST Technical Note on daptomycin [J].
Kahlmeter, G ;
Brown, DFJ ;
MacGowan, AP ;
Mouton, JW ;
Rodloff, A ;
Goldstein, F ;
Odenholt, I ;
Steinbakk, M ;
Stetsiouk, O ;
Soriano, F .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (06) :599-601
[7]  
*NAT COMM CLIN LAB, 1999, GUID NCCLS, V19
[8]   Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections [J].
Pankey, GA ;
Sabath, LD .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) :864-870
[9]   In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains [J].
Rybak, MJ ;
Hershberger, E ;
Moldovan, T ;
Grucz, RG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1062-1066
[10]   Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial [J].
Stalker, DJ ;
Jungbluth, GL .
CLINICAL PHARMACOKINETICS, 2003, 42 (13) :1129-1140